Armeen Mahvash, MD is a Professor in the Department of Interventional Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX.

, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, 

 covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with Armeen Mahvash, MD, about the FDA approval of SIR-Spheres Y-90 resin microspheres for the treatment of patients with unresectable hepatocellular carcinoma. Dr Mahvash is a professor in the Department of Interventional Radiology in the Division of Diagnostic Imaging at The University of Texas MD Anderson Cancer Center in Houston, as well as an assistant professor in the Department of Diagnostic and Interventional Imaging at The University of Texas Medical School at Houston.

In our exclusive interview, Dr Mahvash discussed the significance of this approval, key clinical findings that led to the approval, and how multidisciplinary collaboration is crucial for implementing radioembolization in practice.

That’s all we have for today! Thank you for listening to this episode of 

. Check back throughout the week for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit 

 is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

*OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Podcasts

Dr Mahvash discusses the FDA approval of SIR-Spheres Y-90 resin microspheres for the treatment of patients with unresectable hepatocellular carcinoma. 

FDA Approval Insights: Y-90 Resin Microspheres for Unresectable HCC: With Armeen Mahvash, MD

Professor, Department of Interventional Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX

“[Patients] can get retreatment [with] Y-90 to maintain their transplant eligibility. [In some] patients, chemo-embolization was not as successful. For the patients [who] are transplant eligible, I think [this approval] is a paradigm shift.”

Armeen Mahvash, MD, an interventional radiologist in the Department of Interventional Radiology in the Division of Diagnostic Imaging at The University of Texas MD Anderson Cancer Center in Houston, discussed the clinical impact of 

the FDA approval of SIR-Spheres Y-90 resin microspheres for patients with unresectable hepatocellular carcinoma

Under the approval, Y-90 is indicated for patients with no macrovascular invasion, Child-Pugh A cirrhosis, well-compensated liver function, and good performance status.

The approval was supported by findings from the prospective, multicenter, open-label, single-arm phase 3 DOORwaY

 trial (NCT04736121), which evaluated the first-line efficacy and safety of Y-90 microspheres in patients with unresectable HCC and well-compensated liver function.

According to Mahvash, treatment with SIR-Spheres produced durable local control and high response rates in this population. Findings from DOORwaY

 showed an objective response rate (ORR) of 98.5%. Notably, no patients experienced tumor progression in the treated liver territory at 1 year of follow-up. These results highlight the capacity of Y-90 radioembolization to achieve sustained disease control in patients who are not candidates for surgical resection.

Additionally, Mahvash emphasized the importance of these findings for patients with HCC awaiting liver transplantation. Because transplant wait times in the United States typically exceed 6 months, maintaining tumor stability during this period is essential, Mahvash noted. Historically, transarterial chemoembolization (TACE) has been the standard bridging therapy; however, Y-90 therapy offers a paradigm shift in this setting, providing prolonged local control, he continued. Additionally, patients who experience recurrence can safely undergo retreatment with Y-90 in an effort to preserve transplant eligibility, Mahvash explained.

Videos

Armeen Mahvash, MD, discusses the clinical impact of the FDA approval of SIR-Spheres Y-90 resin microspheres for unresectable hepatocellular carcinoma.

Armeen Mahvash, MD

Articles

FDA Approval Insights: Y-90 Resin Microspheres for Unresectable HCC: With Armeen Mahvash, MD

Dr Mahvash on the Clinical Impact of the FDA Approval of SIR-Spheres Y-90 Resin Microspheres for Unresectable HCC